Cover Image
QR Code

Posaconazole (Noxafil): a new triazole antifungal agent.

Posaconazole is the newest triazole antifungal agent. It is structurally related to itraconazole and has activity against Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. Randomized, double-blind trials have shown posaconazole to be at leas...

Full description

Published in:Baylor University Medical Center Proceedings Vol. 20; no. 2; pp. 188 - 197
Main Author: Greer ND
Format: tables/charts Journal Article
Published: Taylor & Francis Ltd Apr2007
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105723190&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105723190
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        08998280
        1XEP
      jtl: Baylor University Medical Center Proceedings
      issn: 08998280
      maglogo: N
    pubinfo:
      dt: Apr2007
      vid: 20
      iid: 2
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        105723190
        27575204
        27575204
        10.1080/08998280.2007.11928283
        NLM17431456
        105723190
      ppf: 188
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Posaconazole (Noxafil): a new triazole antifungal agent.
      aug:
        au: Greer ND
        affil: Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas.
      sug:
        subj:
          Antifungal Agents Therapeutic Use
          Infection Prevention and Control
          Yeasts Metabolism
          Antifungal Agents Administration and Dosage
          Antifungal Agents Adverse Effects
          Antifungal Agents Pharmacokinetics
          Candida
          Cryptococcus
          Itraconazole Analogs and Derivatives
          Pharmacy and Pharmacology
      ab: Posaconazole is the newest triazole antifungal agent. It is structurally related to itraconazole and has activity against Candida species, Aspergillus species, Cryptococcus neoformans, the zygomycetes, and other filamentous fungi. Randomized, double-blind trials have shown posaconazole to be at least as efficacious as fluconazole for the prevention of invasive fungal infections in immunocompromised patients. It has also shown promising results in the treatment of various fungal infections refractory to other antifungal therapy. The dose of posaconazole is 200 mg orally three times daily for the prevention of invasive fungal infections and 800 mg daily in two to four divided doses for the treatment of invasive fungal infections refractory to other antifungal treatment. All posaconazole doses should be given with food or a nutritional supplement to enhance absorption. The most common adverse effects reported with posaconazole therapy were fever, diarrhea, nausea, vomiting, and headache. Instances of elevated liver enzyme levels, hyperbilirubinemia, and hepatocellular damage were also noted in clinical trials, and these laboratory values should be monitored during treatment with posaconazole.
      pubtype: Academic Journal
      doctype:
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N